Plasma proteomics serves as the cornerstone of clinical biomarker development, yet standalone profiling is plagued by three critical bottlenecks: poor detection of low-abundance proteins, overlapping signals across pathologically similar diseases,...
Zhao et al. (Thu,) studied this question.